Abstract
This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFvsusceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.
Keywords: yeast killer toxin, synthetic peptides, killer mimotopes, antimicrobial therapy, antiidiotypic antibiotics, antiidiotypic therapy
Current Medicinal Chemistry
Title: Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy
Volume: 11 Issue: 13
Author(s): W. Magliani, S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi and L. Polonelli
Affiliation:
Keywords: yeast killer toxin, synthetic peptides, killer mimotopes, antimicrobial therapy, antiidiotypic antibiotics, antiidiotypic therapy
Abstract: This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFvsusceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.
Export Options
About this article
Cite this article as:
Magliani W., Conti S., Salati A., Arseni S., Ravanetti L., Frazzi R. and Polonelli L., Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy, Current Medicinal Chemistry 2004; 11 (13) . https://dx.doi.org/10.2174/0929867043364964
DOI https://dx.doi.org/10.2174/0929867043364964 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Protective Role of Steroids in Ischemia-Reperfusion Injury of the Liver
Current Pharmaceutical Design Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare
Current Medicinal Chemistry A Review of the Pharmacological Interactions of Ivermectin in Several Animal Species
Current Drug Metabolism The Role of T-Type Calcium Channels in Peripheral and Central Pain Processing
CNS & Neurological Disorders - Drug Targets Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Alpha-1-Antitrypsin Deficiency Liver Disease and New Treatment Opportunities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular Antiviral Factors that Target Particle Infectivity of HIV-1
Current HIV Research The Effects of Vitamin B in Depression
Current Medicinal Chemistry Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer
Current Medicinal Chemistry Microarray Analysis of Human Epithelial Cell Responses to Bacterial Interaction
Infectious Disorders - Drug Targets The Generation and Antigen-Specificity of CD4+CD25+ Regulatory T Cells
Inflammation & Allergy - Drug Targets (Discontinued) Alzheimer's Disease Prevention and Use of Traditional Plant Medicines
Letters in Drug Design & Discovery Anti-Invasive and Anti-Metastasis Strategies: New Roads, New Tools and New Hopes
Current Cancer Drug Targets Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study
Current Vascular Pharmacology Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism